MedTrace Logo

Tranexamic Acid to Reduce Delirium After Gastrointestinal Surgery: the TRIGS-D Trial

NCT05470816 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 826

Last updated 2025-12-31

No results posted yet for this study

Summary

Prophylactic TxA administration in patients undergoing major gastrointestinal surgery reduces the incidence of delirium after surgery when compared with placebo. The unifying hypothesis is that systemic and neuro-inflammation lead to neuronal injury and resultant postoperative delirium.

Conditions

  • Surgical Site Infection
  • Dementia
  • Cognition

Interventions

DRUG

Tranexamic Acid 100Mg/ml Inj Vial 10ml

Intervention is from the Tranexamic acid to Reduce Infection after Gastrointestinal Surgery: the TRIGS Trial. A multicentre, pragmatic, double-blind, randomised clinical trial will compare the incidence of surgical site infection and red cell transfusion requirements after IV tranexamic acid and placebo in patients undergoing gastrointestinal surgery

DRUG

Placebo

Normal saline

Sponsors & Collaborators

Principal Investigators

  • Paul S Myles, DSci · Monash University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-01
Primary Completion
2026-08-13
Completion
2026-08-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05470816 on ClinicalTrials.gov